Navigation Links
Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
Date:2/12/2008

- Lead Clinical Program and Two Clinical Candidates Featured -

SOUTH SAN FRANCISCO, Calif., Feb. 12 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, announced four abstracts have been selected for presentation at the meeting of American Association for Cancer Research being held in San Diego on April 12-16, 2008.

"We are pleased to have this opportunity to present important data on both RAV12, Raven's lead therapeutic antibody entering Phase 2 development for the treatment of adenocarcinomas and the promising near-term clinical candidates in our oncology pipeline," stated George Schreiner, M.D., Ph.D., chief executive officer of Raven biotechnologies. "Raven will present significant new data on RAV12 supporting the chemotherapeutic synergies that inform its impending phase 2 trials. In addition, recent discoveries concerning novel epitopes and effector mechanisms associated with two new antibodies targeting cancer stem cells will be presented for the first time. Both antibodies are slated for clinical development. Finally, having advanced the technology to culture cancer stem cells on a sustained basis in vitro, we will present their in vivo biology, using prostate cancer stem cells as an important new model system for understanding the growth and metastasis of human cancer."

The presentations are scheduled as follows:

Oral Presentation in a Minisymposium Session

The anti-B7-H3-4Ig antibody TES7 recognizes cancer stem cell lines, modulates angiogenic factor secretion, and exhibits potent anti-tumor activity in vivo

Session ID: Experimental and Molecular Therapeutics 24

Date and Time: Monday, April 14, 2008, 1:00 PM

Abstract Number: 2555

Poster Sessions

Human prostate cancer stem cell line spontaneously metastasizes in vivo

Session ID: Tumor Biology 5

Date and Time: Sunday, April 13, 2008, 8:00 AM

Abstract Number: 385

The RAV12 monoclonal antibody mediates antitumor activity via multiple mechanisms of action and synergizes with chemotherapeutic agents in vivo
Session ID: Experimental and Molecular Therapeutics 32

Date and Time: Tuesday, April 15, 2008, 8:00 AM

Abstract Number: 4000

Monoclonal antibody KID24 targets human ADAM9 and is a potent inhibitor of tumor growth and metastasis in vivo
Session ID: Experimental and Molecular Therapeutics 32

Date and Time: Tuesday, April 15, 2008, 8:00 AM

Abstract Number: 3989

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, and ovarian cancer.

On November 12, 2007, Raven and VaxGen Inc. (Pink Sheets: VXGN), a biopharmaceutical company, announced that their respective boards of directors unanimously approved a definitive merger agreement. The merger is expected to create a drug development company with a robust pipeline of monoclonal antibody candidates in oncology, proprietary antibody discovery platforms, biopharmaceutical manufacturing capabilities and sufficient cash to fund operations at least through the end of 2009. The merger is expected to close in the first half of 2008.


'/>"/>
SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
2. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
3. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
10. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
11. Amyris Biotechnologies Announces $70 Million Series B Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) ... December 31, 2015. --> --> ... net loss of $29.3 million, or $0.34 loss per share, compared ... share for the same period in 2014. For the year ended ... million, or $1.05 loss per share, as compared to a net ...
(Date:2/11/2016)... and GERMANTOWN, Maryland , ... Frankfurt Prime Standard: QIA) today announced the introduction of ... gene expression profiling, expanding QIAGEN,s portfolio of Sample to ... researchers to select from over 20,000 human genes and ... between genes, cellular phenotypes and disease processes. --> ...
(Date:2/11/2016)... ATLANTA , Feb. 11, 2016  Spectra BioPharma ... Organization (CSO) that provides biopharma companies the experience, ... implement and deploy outsourced sales teams. Created in ... team addresses both the strategic and tactical needs ... innovative sales solutions through both personal and non-personal ...
(Date:2/11/2016)... (PRWEB) , ... February 11, ... ... business-to-business publication dedicated to delivering cutting-edge information focused on the development and ... Sciences to become a premier sponsor of the 2016 BioProcess International Awards ...
Breaking Biology Technology:
(Date:2/11/2016)... 2016  Vigilant Solutions announces today that its license plate ... by Lee,s Summit Police Department to ... arrest of a homicide suspect. Kansas City ... 65 square miles and is home to roughly 100,000 residents. ... single mobile license plate reader system and also leverages Vigilant,s ...
(Date:2/8/2016)... PRAGUE, Czech Republic , February 8, 2016 ... first EU-regulated global payment platform which presents innovation ... Voice Biometrics Authentication feature called VoiceKey. --> ... payment platform which presents innovation for clients, comfort ... feature called VoiceKey. --> Worldcore ...
(Date:2/3/2016)... , February 3, 2016 ... market research report "Automated Fingerprint Identification System Market by ... Search), Application (Banking & Finance, Government, Healthcare, and Transportation) ... MarketsandMarkets, the market is expected to be worth USD ... 21.0% between 2015 and 2020. The transformation and technology ...
Breaking Biology News(10 mins):